Commentary: Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis

David Beauvais, Kévin-James Wattebled, Elodie Drumez, and Ibrahim Yakoub-Agha

UNIV. LILLE, CHU LILLE, DEPARTMENT OF HEMATOLOGY, LILLE, FRANCE, 2UNIV. LILLE, CHU LILLE, INSERM, INFINITE, LILLE, FRANCE, 3CHU LILLE, DEPARTMENT OF BIOSTATISTICS, LILLE, FRANCE, 4UNIV. LILLE, CHU LILLE, ULR 2694 - METRICS: ÉVALUATION DES TECHNOLOGIES DE SANTÉ ET DES PRATIQUES MÉDICALES, LILLE, FRANCE

KEYWORDS
meta-analysis, immortal time bias, allogeneic hematopoietic stem cell transplantation, hypomethylating agent, acute myeloid leukemia, myelodysplastic syndromes

Introduction

We read with great interest the study by Kungwankiattichai et al. entitled: “Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis” (1). Indeed, the value of maintenance therapy with hypomethylating agents (HMA) in the post-transplant setting has long been debated. In addition, 2022 European LeukemiaNet does not recommend subcutaneous azacytidine maintenance (2). In the current meta-analysis, Kungwankiattichai et al.
reported a higher overall survival and relapse-free survival of the HMA maintenance group compared to the observation group. Moreover, the cumulative incidence of relapse and non-relapse mortality was significantly lower in those who received HMA. Therefore, the authors concluded that HMA maintenance after allogeneic hematopoietic cell transplantation (allo-HCT) was beneficial in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

**Immortal time bias**

As meta-analysis could be useful to pool individual studies to address a question, we believe that the meta-analysis in the context of post-transplant setting is still challenging. Such work may even amplify the bias or misinterpretation involved in many retrospective studies. Indeed, on one hand, patients who received HMA after transplant (at day+60 post-transplant for example) are only those who survived by day+60. On the other hand, patients who died prematurely are by default in the control group without HMA due to a well-known statistical bias called “immortal time bias” (3, 4). The elapsed time between allo-HCT and HMA initiation is an immortality period during which subjects who were candidate to receive HMA but died prematurely are counted as patients without HMA. Consequently, the immortal time bias generally tends to falsely attribute significant benefit to the study drug group.

The meta-analysis of Kungwankiattichai et al. consisted of 14 studies including 10 retrospective studies and 4 prospective studies. To avoid immortal time bias, two randomized studies were designed with a randomization occurring after transplant (between 42 and 100 days) (5, 6). Of note, Gao et al. observed reduced incidence of relapse with decitabine maintenance coupled with granulocyte colony-stimulating factor (G-CSF) while Oran et al. did not find any beneficial of 5-azacytidine (AZA) maintenance. From the outset, one may question the relevance of combining 2 studies using different drugs including one with additional G-CSF.

In reviewing the other studies included in the meta-analysis, some had not accounted the immortal time bias (7–11). All patients were included at time of transplantation leading to an overestimation of the efficacy of HMA. Moreover, while the studies account for confounding bias, the authors of the meta-analysis combined the outcomes of individual studies by pooling unadjusted risk ratio without accounting for confounding factors and without considering that the outcomes were censored events. In addition, some studies used prophylactic donor lymphocytes infusion (7, 12) or gemtuzumab ozaogamicin (8), which may further overestimate the effect of HMA. Finally, data recovery was probably an issue because some of studies were not published as regular article but as a letter or as a poster at conference (7) and indeed we were not able to find 3 analyzed studies (Ovechkina et al., Américo et al., Booth et al., for full references see Kungwankiattichai et al.).

**Discussion**

For all these limitations, we believe that it is difficult to draw any firm conclusion based on Kungwankiattichai et al. There are ways to avoid immortality bias and every retrospective study should apply them. One is to avoid adding an immortal period by beginning follow-up of exposed and unexposed patients at the end of the identified immortal period (13). Alternatively, it is possible to compare 2 periods with a different treatment strategy in each period (e.g., all patients received treatment in period 1 and no patients received treatment in period 2). In addition, the use of a model that considers exposure as a time-dependent variable leads to a more potent effect. This method considers patients as unexposed from the beginning of the follow-up until the date on which they meet the criteria defining exposure and considers them as exposed after this date (14, 15). At last, a nested case-control design is a robust statistical method which has already demonstrated its ability in other areas (16).

We recently published an article of AZA as post-transplant maintenance in high-risk myeloid malignancies (17). In this retrospective study including 185 patients (65: AZA, 120: control group), the two groups were similar in terms of 2-year incidence of relapse, overall survival, and event-free survival. But before stating this result, we have been careful to consider the following points. First, we decided to exclude all patients who died, relapsed, or developed grade ≥2 acute graft-vs.-host disease before day+60, which avoided the immortal time bias. Second, we used “time-to-event” methods (Kaplan-Meier, Kalbkleisch and Prentice) to estimate survival and account for censored observations and competing risks or incidence. Third, we used multivariable analysis (multivariable Cox and Fine-Gray regression models) to avoid confusion bias and estimate the own effect of AZA.

In conclusion, meta-analyses are the highest level of evidence. But the best way to perform such analyses is to carry them out with accurate and complete data from the original studies. The flawed approach to data design and analysis, leading to an immortal time bias, may lead to a false conclusion, and generally favor the study treatment (14). Because of this limitation, we believe that to assess the benefit of HMA maintenance treatment after allograft, only a randomized study can allow a definitive conclusion.

**Author contributions**

DB and K-JW analyzed the studies and wrote the initial version of the manuscript. ED identified the statistical issues.
IY-A wrote the final version of the manuscript. All authors read and approved the final manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Kongwanakitthisi S, Ponvilawan B, Roy C, Tunping P, Kuchenbauer F, Owattanapanich W. Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. Front Med. (2022) 9:801632. doi: 10.3389/fmed.2022.801632

2. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Domnert H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. (2022) 140:1345–77. doi: 10.1182/blood.2022016867

3. Sylvestre MP, Huszti E, Hanley IA. Do OSCAR winners live longer than less successful peers? A reanalysis of the evidence. Ann Intern Med. (2006) 145:361–3. Discussion 392. doi: 10.7326/0003-4819-145-5-200609050-00009

4. Suisa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. (2003) 168:49–53. doi: 10.1164/rccm.200210-1231OC

5. Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. (2020) 4:5580–8. doi: 10.1182/bloodadvances.202002544

6. Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol. (2020) 38:4249–59. doi: 10.1200/JCO.20.01277

7. Joris M, Lebon D, Charbonnier A, Morel P, Gruson B, Caulier A, et al. Immunomodulation with azacitidine and donor lymphocyte infusion following sequential conditioning allogeneic stem cell transplantation improves outcome of unfavorable AML. Blood. (2019) 134:660. doi: 10.1182/blood.2019-131314

8. Oshikawa G, Kakihana K, Saito M, Aoki J, Naito S, Kobayashi T, et al. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukemia. Br J Haematol. (2015) 169:756–9. doi: 10.1111/bjh.13248

9. Maples KT, Sabo RE, McCarty JM, Toor AA, Hawks KG. Maintenance azacitidine after myelodysplastic hematopoietic stem cell transplantation for myeloid malignancies. Leuk Lymphoma. (2018) 59:2836–41. doi: 10.1080/10428194.2018.1443334

10. Ma Y, Qu C, Dai H, Yin J, Li Z, Chen J, et al. Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia. Bone Marrow Transplant. (2020) 55:1206–8. doi: 10.1038/s41409-019-0677-z

11. Keruakous AR, Holter-Chakraborty J, Schmidt SA, Khawandanah MO, Selby G, Yuen C. Azacitidine maintenance therapy post-allogeneic stem cell transplantation in poor-risk acute myeloid leukemia. Hematol Oncol Stem Cell Ther. (2021). doi: 10.1016/j.hemonc.2021.03.001. [Epub ahead of print].

12. Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, et al. Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. (2019) 54:1815–26. doi: 10.1038/s41409-019-0536-y

13. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol. (2005) 162:1016–23. doi: 10.1093/aje/kwi307

14. Suisa S. Immortal time bias in observational studies of drug effects. Pharmacoeconom Drug Saf. (2007). 16:241–9. doi: 10.1002/pds.1357

15. Faillie JL, Suisa S. Le biais de temps immortel dans les études pharmacoépidémiologiques : définition, solutions et exemples. Thérapie. (2015) 70:259–63. doi: 10.2535/therapie.2014207

16. Kiri VA, Pride NR, Sortino JB, Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. (2005) 172:460–4. doi: 10.1164/rccm.200502-210OC

17. Watebled KI, Drumer E, Coiteux V, Magro L, Srour M, Chauvet P, et al. Single-agent 5-azacitidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. (2022) 101:1321–31. doi: 10.1007/s00277-022-04821-y

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.